EXPRESSION PATTERN OF miR-125b-2, -155, -221, AND -320a IS ASSOCIATED WITH RESPONSE OF BREAST CANCER PATIENTS TO TAMOXIFEN.

Q3 Medicine Experimental oncology Pub Date : 2022-12-01 DOI:10.32471/exp-oncology.2312-8852.vol-44-no-4.19152

O Pridko, T Borikun, O Rossylna, M Rishko, A V Rusyn

{"title":"EXPRESSION PATTERN OF miR-125b-2, -155, -221, AND -320a IS ASSOCIATED WITH RESPONSE OF BREAST CANCER PATIENTS TO TAMOXIFEN.","authors":"O Pridko, T Borikun, O Rossylna, M Rishko, A V Rusyn","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-4.19152","DOIUrl":null,"url":null,"abstract":"Background: Hormonal therapy is one of the main methods of comprehensive treatment of patients with locally advanced breast cancer (BC). Despite the intensive search for molecules associated with the aggressiveness of the tumor process, currently there are no reliable markers predicting response to neoadjuvant hormonal therapy (NHT).Aim: To investigate the correlation between miR-125b-2, -155, -221, -320a expression in tumor tissue and HER2/neu status and response to tamoxifen treatment in BC patients.Materials and methods: Expression levels of miR-125b-2, -155, -221, and -320a were analyzed in biopsy samples of 50 BC patients using a real-time polymerase chain reaction.Results: We found that levels of miR-125b-2, -155, -221, and -320a were 1.72, 1.65, 1.85, and 2.89 times higher in BC biopsy samples expressing estrogen/progesterone receptors and HER2/neu compared with HER2/neu-negative luminal tumors. Patients with a luminal BC showing higher levels of miR-125b-2 and miR-320a expression before therapy demonstrated better response to NHT with tamoxifen. A strong correlation was calculated for miR-221 expression and response to NHT (r = 0.61).Conclusions: The high levels of miR-125b-2, -155, -221, and -320a in tumor tissue are associated with the HER2/neu-positive status of luminal BC subtypes. Tumor samples of patients showing the low response to NHT with tamoxifen are characterized by lower expression of miR-125b-2 and -320a. Hence, miR-125b-2 and -320a could be considered as putative predictive biomarkers associated with tamoxifen sensitivity of hormone-dependent BC.","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 4","pages":"295-299"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-4.19152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Hormonal therapy is one of the main methods of comprehensive treatment of patients with locally advanced breast cancer (BC). Despite the intensive search for molecules associated with the aggressiveness of the tumor process, currently there are no reliable markers predicting response to neoadjuvant hormonal therapy (NHT).

Aim: To investigate the correlation between miR-125b-2, -155, -221, -320a expression in tumor tissue and HER2/neu status and response to tamoxifen treatment in BC patients.

Materials and methods: Expression levels of miR-125b-2, -155, -221, and -320a were analyzed in biopsy samples of 50 BC patients using a real-time polymerase chain reaction.

Results: We found that levels of miR-125b-2, -155, -221, and -320a were 1.72, 1.65, 1.85, and 2.89 times higher in BC biopsy samples expressing estrogen/progesterone receptors and HER2/neu compared with HER2/neu-negative luminal tumors. Patients with a luminal BC showing higher levels of miR-125b-2 and miR-320a expression before therapy demonstrated better response to NHT with tamoxifen. A strong correlation was calculated for miR-221 expression and response to NHT (r = 0.61).

Conclusions: The high levels of miR-125b-2, -155, -221, and -320a in tumor tissue are associated with the HER2/neu-positive status of luminal BC subtypes. Tumor samples of patients showing the low response to NHT with tamoxifen are characterized by lower expression of miR-125b-2 and -320a. Hence, miR-125b-2 and -320a could be considered as putative predictive biomarkers associated with tamoxifen sensitivity of hormone-dependent BC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

miR-125b-2， -155， -221和-320a的表达模式与乳腺癌患者对他莫昔芬的反应有关。

背景:激素治疗是局部晚期乳腺癌(BC)综合治疗的主要方法之一。尽管对与肿瘤过程侵袭性相关的分子进行了深入的研究，但目前还没有可靠的标志物预测对新辅助激素治疗(NHT)的反应。目的:探讨BC患者肿瘤组织中miR-125b-2、-155、-221、-320a表达与HER2/neu状态及对他莫昔芬治疗反应的相关性。材料和方法:采用实时聚合酶链反应分析50例BC患者活检样本中miR-125b-2、-155、-221和-320a的表达水平。结果:我们发现，在表达雌激素/孕激素受体和HER2/neu的BC活检样本中，miR-125b-2、-155、-221和-320a的水平比HER2/neu阴性的腔内肿瘤高1.72、1.65、1.85和2.89倍。在治疗前显示miR-125b-2和miR-320a表达水平较高的管腔BC患者对他莫昔芬NHT的反应更好。计算miR-221的表达与NHT的反应有很强的相关性(r = 0.61)。结论:肿瘤组织中高水平的miR-125b-2、-155、-221和-320a与腔内BC亚型的HER2/新阳性状态相关。他莫昔芬对NHT反应低的患者肿瘤样本的特点是miR-125b-2和-320a的表达较低。因此，miR-125b-2和-320a可以被认为是与激素依赖性BC的他莫昔芬敏感性相关的推定预测性生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Experimental oncology Medicine-Oncology

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The Experimental Oncology is an English-language journal that publishes review articles, original contributions, short communications, case reports and technical advances presenting new data in the field of experimental and fundamental oncology. Manuscripts should be written in English, contain original work, which has not been published or submitted for publication elsewhere. It also implies the transfer of the Copyright from the author to “Experimental Oncology”. No part of journal publications may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the publisher.